CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 ...
BioSpace

Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

CRISPR updates early-stage trial data for heart disease therapy

CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...

Intellia tumbles after patient dies following Crispr treatment

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
pharmaphorum

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...
Fierce Biotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
MedPage Today on MSN

Trial Patient Dies After Receiving CRISPR Gene Therapy

A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...